Cooper Companies Valuation
Is COO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of COO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COO * (MX$1740.81) is trading above our estimate of fair value (MX$1551.62)
Significantly Below Fair Value: COO * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COO *?
Key metric: As COO * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is COO *'s PE Ratio? | |
|---|---|
| PE Ratio | 69.8x |
| Earnings | US$290.80m |
| Market Cap | US$20.31b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.3x |
| Enterprise Value/EBITDA | 26.5x |
| PEG Ratio | 3.3x |
Price to Earnings Ratio vs Peers
How does COO *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 32.5x | ||
COLO B Coloplast | 40.2x | 12.9% | DKK 202.9b |
ALGN Align Technology | 37.8x | 17.5% | US$16.5b |
SOLV Solventum | 16.2x | 6.0% | US$11.7b |
ALC Alcon | 36x | 9.4% | CHF 37.2b |
COO * Cooper Companies | 69.8x | 21.1% | Mex$20.3b |
Price-To-Earnings vs Peers: COO * is expensive based on its Price-To-Earnings Ratio (69.8x) compared to the peer average (44.6x).
Price to Earnings Ratio vs Industry
How does COO *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 9 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 9 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: COO * is expensive based on its Price-To-Earnings Ratio (69.8x) compared to the Global Medical Equipment industry average (28.1x).
Price to Earnings Ratio vs Fair Ratio
What is COO *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 69.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COO *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$1,749.61 0% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Nov ’25 | n/a | Mex$1,749.61 0% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Oct ’25 | Mex$2,121.50 | Mex$1,749.61 -17.5% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Sep ’25 | Mex$1,823.00 | Mex$1,749.61 -4.0% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Aug ’25 | n/a | Mex$1,749.61 0% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Jul ’25 | Mex$1,579.00 | Mex$1,749.61 +10.8% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Jun ’25 | Mex$1,535.03 | Mex$1,749.61 +14.0% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| May ’25 | Mex$1,525.00 | Mex$1,749.61 +14.7% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Apr ’25 | n/a | Mex$1,749.61 0% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Mar ’25 | Mex$1,740.81 | Mex$1,749.61 +0.5% | 9.7% | Mex$1,974.16 | Mex$1,434.67 | n/a | 16 |
| Feb ’25 | n/a | Mex$1,671.90 0% | 8.2% | Mex$1,879.52 | Mex$1,439.54 | n/a | 16 |
| Jan ’25 | n/a | Mex$1,639.77 0% | 8.2% | Mex$1,825.37 | Mex$1,430.58 | n/a | 16 |
| Dec ’24 | Mex$1,429.03 | Mex$1,698.49 +18.9% | 7.6% | Mex$1,861.21 | Mex$1,484.64 | n/a | 15 |
| Nov ’24 | n/a | Mex$1,773.79 0% | 7.6% | Mex$1,940.75 | Mex$1,548.09 | n/a | 15 |
| Oct ’24 | n/a | Mex$1,765.58 0% | 7.6% | Mex$1,931.07 | Mex$1,514.14 | Mex$2,121.50 | 14 |
| Sep ’24 | n/a | Mex$1,728.97 0% | 7.3% | Mex$1,880.04 | Mex$1,474.12 | Mex$1,823.00 | 14 |
| Aug ’24 | n/a | Mex$1,680.09 0% | 8.3% | Mex$1,841.19 | Mex$1,359.97 | n/a | 14 |
| Jul ’24 | n/a | Mex$1,712.40 0% | 7.8% | Mex$1,854.39 | Mex$1,398.32 | Mex$1,579.00 | 14 |
| Jun ’24 | n/a | Mex$1,710.27 0% | 9.2% | Mex$1,886.99 | Mex$1,404.27 | Mex$1,535.03 | 13 |
| May ’24 | n/a | Mex$1,691.36 0% | 8.0% | Mex$1,945.48 | Mex$1,447.80 | Mex$1,525.00 | 12 |
| Apr ’24 | n/a | Mex$1,604.41 0% | 8.5% | Mex$1,764.66 | Mex$1,266.94 | n/a | 12 |
| Mar ’24 | n/a | Mex$1,636.21 0% | 9.6% | Mex$1,812.34 | Mex$1,318.07 | Mex$1,740.81 | 12 |
| Feb ’24 | Mex$1,637.50 | Mex$1,636.21 -0.08% | 9.6% | Mex$1,812.34 | Mex$1,318.07 | n/a | 12 |
| Jan ’24 | Mex$1,937.25 | Mex$1,666.90 -14.0% | 8.4% | Mex$1,833.99 | Mex$1,369.38 | n/a | 12 |
| Dec ’23 | Mex$1,937.25 | Mex$1,628.57 -15.9% | 8.5% | Mex$1,784.33 | Mex$1,350.31 | Mex$1,429.03 | 10 |
| Nov ’23 | Mex$1,937.25 | Mex$1,677.73 -13.4% | 9.2% | Mex$1,882.55 | Mex$1,405.64 | n/a | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Teladoc Health
US$1.6b
Provides virtual healthcare services worldwide.
TDOC *
US$183.00
7D
-1.1%
1Y
-35.5%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a